CD20 and/or CD19 Positive B-Cell Hematologic Malig

A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies

Schedule an Appointment

Select an appointment date and time from available spots listed below.